Canada markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
14.87+0.14 (+0.95%)
At close: 04:00PM EST
14.78 -0.09 (-0.61%)
After hours: 07:53PM EST
Full screen
Loading interactive chart...
  • Bloomberg

    Japan’s Government Stayed Out of Currency Markets in November

    (Bloomberg) -- Japan stayed out of the foreign exchange market in November, after the yen made gains amid growing expectations that the Federal Reserve will moderate its pace of interest rate hikes.Most Read from BloombergScientists Revive 48,500-Year-Old ‘Zombie Virus’ Buried in IceNYC Becomes One Billionaire Family’s Haven From China Property CrashThese Are the Best and Worst Cities for Expats to Live and Work InBanks Stuck With $42 Billion Debt Seize Chance to Offload ItThe finance ministry d

  • Business Wire

    Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration

    OSAKA, Japan and CAMBRIDGE, Massachusetts, November 22, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review of the Biologics License Application (BLA) for TAK-003, the company’s investigational dengue vaccine candidate. In the U.S., TAK-003 is being evaluated for the prevention of dengue disease caused by any dengue virus serotype in individuals 4 years through 60 years of age.

  • Motley Fool

    Why Puma Biotechnology's Shares Jumped 20% on Monday

    The biopharmaceutical company specializes in cancer therapies. Its stock got a boost on Monday when a Takeda Pharmaceutical (NYSE: TAK) candidate, ponatinib, hit its primary goal in a phase 3 clinical trial as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia. The blood cancer therapy works by slowing the activity of BCR-ABL1, a gene sequence found in an abnormal chromosome 22, often seen in people with certain types of leukemia.